Although the tumor stage, residual disease after surgical debulking, response to chemotherapy, and BRCA1/2-mutation status all affect the outcome of ovarian cancer, the variability in PFS and OS among patients with similar clinical and pathological characteristics makes it difficult to reliably predict outcome. The gene discussed is BRCA1; the disease is neoplasm.